Initial Approach to Non-Clostridioides difficile Colitis

Assessment and Classification

• The initial treatment for non-C. difficile colitis should focus on 5-aminosalicylates for mild to moderate disease, while moderate to severe disease requires corticosteroids or biologic agents depending on disease severity, as recommended by the American Gastroenterological Association 1
• Disease extent should be classified as proctitis, left-sided, or extensive/pancolitis, as this influences treatment approach 1

Treatment Algorithm by Disease Severity

Mild to Moderate Disease

• High-dose oral mesalazine (5-aminosalicylate) at 4g daily is recommended as first-line treatment for mild to moderate disease, according to the European Crohn’s and Colitis Organisation 2, 1
• Topical mesalazine may be effective for left-sided colonic disease of mild to moderate activity, as suggested by the American Gastroenterological Association 2

Moderate to Severe Disease

• Oral corticosteroids such as prednisolone 40mg daily are appropriate for patients with moderate to severe disease, or those failing mesalazine therapy, as recommended by the European Crohn’s and Colitis Organisation 2, 1
• Prednisolone should be reduced gradually over 8 weeks to avoid early relapse, according to the American Gastroenterological Association 2

Severe or Fulminant Disease

• Intravenous steroids (hydrocortisone 400mg/day or methylprednisolone 60mg/day) are recommended for severe disease, as suggested by the European Crohn’s and Colitis Organisation 2
• Early surgical consultation should be considered for patients with severe disease not responding to medical therapy, according to the American Gastroenterological Association 1

Adjunctive Therapies

• Elemental or polymeric diets are appropriate adjunctive therapy, but less effective than corticosteroids as primary treatment, as recommended by the European Society for Clinical Nutrition and Metabolism 2
• Azathioprine (1.5-2.5mg/kg/day) or mercaptopurine (0.75-1.5mg/kg/day) may be used as adjunctive therapy and steroid-sparing agents, according to the American Gastroenterological Association 2

Biologic Therapy Options

• Biologic agents should be considered for moderate-severe disease failing conventional therapy, as recommended by the American Gastroenterological Association 1
• Infliximab 5mg/kg is effective, but should be avoided in patients with obstructive symptoms, according to the European Crohn’s and Colitis Organisation 2

Important Clinical Considerations

• Patients should be encouraged to participate actively in treatment decisions, as recommended by the European Crohn’s and Colitis Organisation 2
• Surgery should be considered for those who have failed medical therapy, according to the American Gastroenterological Association 2

Maintenance Therapy

• Maintenance therapy is generally recommended after achieving remission, especially for patients with left-sided or extensive disease, as suggested by the American Gastroenterological Association 1
• Options include 5-aminosalicylates, azathioprine, or mercaptopurine, according to the European Crohn’s and Colitis Organisation 1